Pipeline Monitor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020, with cancer treatments representing one third (35%) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, at 13%, and are expected to grow in importance in response to the COVID-19 pandemic. Meds Pipeline Monitor 2020 reviewed 935 new medicines in late stages of clinical evaluation to highlight drugs that could potentially impact the Canadian health care system. Among these, the PMPRB identified 16 late-stage new medicines, including five gene therapies, that may offer breakthroughs in treating previously unmet needs or have the potential to treat large patient populations, as well as six new medicines currently under review by Heath Canada. The report also provides an overview of the fast-moving pipeline for medicines and v

National prescription drug utilization information systemHealth canadaPatented medicine prices review boardMeds pipeline monitorPipeline monitorMeds entry watchPatented medicine prices reviewதேசிய ப்ரிஸ்க்ரிப்ஶந் மருந்து பயன்பாடு தகவல் அமைப்புஆரோக்கியம் கனடாகாப்புரிமை பெற்றது மருந்து ப்ரைஸஸ் விமர்சனம் பலகைமேட்ச் குழாய் மானிட்டர்குழாய் மானிட்டர்மேட்ச் நுழைவு வாட்ச்காப்புரிமை பெற்றது மருந்து ப்ரைஸஸ் விமர்சனம்